Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines
Globenewswire·2025-11-07 20:00
Data from studies conducted by investigators at the National Cancer Institute at NCI laboratories, part of a multi-year research effort, will be presented at SITCDover, DE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) (“AlphaTON”) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (“Cyncado”), today announced a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 5 to 9, 2025, in Nation ...